Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Using a comprehensive approach of clinico-behavioral testing, neuroimaging and
pharmacogenetics, the researchers will examine the clinical effects of sodium oxybate and the
matched placebo on voice symptoms in spasmodic dysphonia and voice tremor.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Kristina Simonyan
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)